Farallon Capital Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-451,700
| Closed | -$46.1M | – | 184 |
|
|
2023
Q2 | $46.1M | Buy |
451,700
+126,700
| +39% | +$12.9M | 0.23% | 67 |
|
|
2023
Q1 | $29.5M | Sell |
325,000
-7,000
| -2% | -$636K | 0.16% | 70 |
|
|
2022
Q4 | $12.6M | Buy |
+332,000
| New | +$12.6M | 0.07% | 94 |
|
|
2020
Q1 | – | Sell |
-75,000
| Closed | -$15.3M | – | 115 |
|
|
2019
Q4 | $15.3M | Sell |
75,000
-107,060
| -59% | -$21.9M | 0.1% | 88 |
|
|
2019
Q3 | $14.6M | Sell |
182,060
-617,940
| -77% | -$49.6M | 0.11% | 77 |
|
|
2019
Q2 | $75.5M | Buy |
800,000
+50,000
| +7% | +$4.72M | 0.49% | 48 |
|
|
2019
Q1 | $64.1M | Buy |
750,000
+50,000
| +7% | +$4.27M | 0.48% | 46 |
|
|
2018
Q4 | $39.3M | Buy |
700,000
+26,500
| +4% | +$1.49M | 0.29% | 49 |
|
|
2018
Q3 | $55.1M | Buy |
+673,500
| New | +$55.1M | 0.33% | 46 |
|